{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:53:58Z","timestamp":1761058438403,"version":"build-2065373602"},"reference-count":42,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T00:00:00Z","timestamp":1147219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twenty patients were treated with arsenic trioxide at a dose of 0.25 mg\/kg\/day and administered intravenously over 1 to 2 hours on Days 1\u20105 and repeated every 28 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>There were no complete or partial responses. The median progression\u2010free survival was 1 month and the median overall survival was 2 months. Three patients died as a result of adverse events believed to be possibly related to treatment: ventricular arrhythmia, adult respiratory distress syndrome, and pneumonitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>In the current study, arsenic trioxide in the dose regimen and schedule employed was found to have no activity in men with refractory germ cell malignancies. Treatment was associated with severe toxicity. Dismal overall survival reflects the poor outcome in this patient group and highlights the acute need for new agents with activity in refractory germ cell neoplasms. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21925","type":"journal-article","created":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T19:12:25Z","timestamp":1147288345000},"page":"2624-2629","source":"Crossref","is-referenced-by-count":32,"title":["Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies"],"prefix":"10.1002","volume":"106","author":[{"given":"Tomasz M.","family":"Beer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig R.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim A.","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,5,10]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_5_2_2","DOI":"10.1200\/JCO.1990.8.11.1777"},{"doi-asserted-by":"publisher","key":"e_1_2_5_3_2","DOI":"10.1200\/JCO.1997.15.2.594"},{"doi-asserted-by":"publisher","key":"e_1_2_5_4_2","DOI":"10.1200\/JCO.1998.16.7.2500"},{"doi-asserted-by":"publisher","key":"e_1_2_5_5_2","DOI":"10.1200\/JCO.1996.14.10.2638"},{"doi-asserted-by":"publisher","key":"e_1_2_5_6_2","DOI":"10.1182\/blood.V89.9.3354"},{"key":"e_1_2_5_7_2","first-page":"58","article-title":"Arsenic trioxide treated 72 cases of acute promyelocytic leukemia","volume":"17","author":"Zhang P","year":"1996","journal-title":"Chin J Hematol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_8_2","DOI":"10.1056\/NEJM199811053391901"},{"key":"e_1_2_5_9_2","first-page":"3084","article-title":"U.S. multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL)","author":"Soignet S","year":"1999","journal-title":"Proc Am Soc Hematol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_10_2","DOI":"10.1002\/ajh.10138"},{"doi-asserted-by":"publisher","key":"e_1_2_5_11_2","DOI":"10.1002\/cncr.11314"},{"doi-asserted-by":"publisher","key":"e_1_2_5_12_2","DOI":"10.1182\/blood.V88.3.1052.1052"},{"doi-asserted-by":"publisher","key":"e_1_2_5_13_2","DOI":"10.1182\/blood.V89.5.1701"},{"doi-asserted-by":"publisher","key":"e_1_2_5_14_2","DOI":"10.1182\/blood.V94.6.2102"},{"doi-asserted-by":"publisher","key":"e_1_2_5_15_2","DOI":"10.1093\/jnci\/90.2.124"},{"doi-asserted-by":"publisher","key":"e_1_2_5_16_2","DOI":"10.1038\/sj.leu.2402599"},{"doi-asserted-by":"publisher","key":"e_1_2_5_17_2","DOI":"10.1111\/j.1365-2141.2004.04941.x"},{"doi-asserted-by":"publisher","key":"e_1_2_5_18_2","DOI":"10.1073\/pnas.0400053101"},{"doi-asserted-by":"publisher","key":"e_1_2_5_19_2","DOI":"10.1200\/JCO.2003.01.149"},{"doi-asserted-by":"publisher","key":"e_1_2_5_20_2","DOI":"10.1038\/sj.thj.6200374"},{"doi-asserted-by":"publisher","key":"e_1_2_5_21_2","DOI":"10.3109\/10428190009057628"},{"key":"e_1_2_5_22_2","first-page":"33","article-title":"Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro","volume":"4","author":"Shen ZY","year":"1999","journal-title":"Int J Mol Med."},{"doi-asserted-by":"publisher","key":"e_1_2_5_23_2","DOI":"10.1016\/S0959-8049(99)00106-9"},{"key":"e_1_2_5_24_2","first-page":"6033","article-title":"Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown","volume":"59","author":"Lew YS","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_5_25_2","first-page":"753","article-title":"P53 status as a determinant of response to arsenic trioxide in human Burkitt's lymphoma, prostate and breast cancer cells","volume":"41","author":"Ma Y","year":"2000","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_26_2","first-page":"68","article-title":"Mechanism of arsenic trioxide induced growth inhibition and apoptosis in malignant cells","volume":"39","author":"Dai J","year":"1998","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_27_2","first-page":"397","article-title":"Arsenic trioxide (AS2O3) activity spectrum in human tumors","volume":"40","author":"Nagourney RA","year":"1999","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_28_2","first-page":"588","article-title":"Arsenic trioxide is an equipotent inducer of apoptosis in androgen\u2010dependent and androgen\u2010independent LNCaP prostate cancer cell sublines","volume":"39","author":"Zhou DC","year":"1998","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_29_2","first-page":"4957","article-title":"Arsenic trioxide\u2010mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines","volume":"6","author":"Uslu R","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_30_2","first-page":"416","article-title":"Arsenic\u2010induced apoptosis in solid tumor cells","volume":"41","author":"Akao Y","year":"2000","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_31_2","first-page":"155","article-title":"Induction of apoptosis by APAF\u20101 and cytochrome C\u2010dependent activation of caspace after treatment with arsenic trioxide (AS2O3) in head and neck cancer cell PCI\u20101","volume":"41","author":"Seol JG","year":"2000","journal-title":"Proc Am Assoc Cancer Res."},{"doi-asserted-by":"publisher","key":"e_1_2_5_32_2","DOI":"10.1006\/bbrc.1999.1697"},{"key":"e_1_2_5_33_2","first-page":"227","article-title":"Cytotoxicity of arsenic trioxide in cancer cell lines","volume":"39","author":"Yang CH","year":"1998","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_34_2","first-page":"3053","article-title":"Arsenic induces apoptosis through a c\u2010Jun NH2\u2010terminal kinase\u2010dependent, p53\u2010independent pathway","volume":"59","author":"Huang C","year":"1999","journal-title":"Cancer Res."},{"doi-asserted-by":"publisher","key":"e_1_2_5_35_2","DOI":"10.1046\/j.1365-2141.1998.00869.x"},{"key":"e_1_2_5_36_2","first-page":"155","article-title":"The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells","volume":"5","author":"Shen ZY","year":"2000","journal-title":"Int J Mol Med."},{"doi-asserted-by":"publisher","key":"e_1_2_5_37_2","DOI":"10.1182\/blood.V96.4.1525"},{"key":"e_1_2_5_38_2","first-page":"3065","article-title":"Arsenic trioxide\u2010mediated growth inhibition in MC\/CAR myeloma cells via cell cycle arrest in association with induction of cyclin\u2010dependent kinase inhibitor, p21, and apoptosis","volume":"60","author":"Park WH","year":"2000","journal-title":"Cancer Res."},{"doi-asserted-by":"publisher","key":"e_1_2_5_39_2","DOI":"10.1038\/sj.bjc.6690766"},{"doi-asserted-by":"publisher","key":"e_1_2_5_40_2","DOI":"10.1182\/blood.V93.1.268"},{"key":"e_1_2_5_41_2","first-page":"201a","article-title":"Clinical and pharmacologic study of arsenic trioxide (As2O3) in patients with solid tumors","volume":"19","author":"Soignet S","year":"2000","journal-title":"Proc Am Soc Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_42_2","DOI":"10.1023\/A:1016270206374"},{"key":"e_1_2_5_43_2","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1200\/jco.2004.22.90140.4114","article-title":"A multi\u2010center phase II study of arsenic trioxide (AT) in patients (Pts) with advanced pancreatic cancer (PC) refractory to gemcitabine","volume":"22","author":"Aklilu M","year":"2004","journal-title":"J Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21925","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:45:55Z","timestamp":1760269555000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,10]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,6,15]]}},"alternative-id":["10.1002\/cncr.21925"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21925","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2006,5,10]]}}}